[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100271464":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":10,"locations":19,"responsibleParty":204,"collaborators":10,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":208,"sex":214,"minAge":215,"maxAge":10,"enrollmentInfo":216,"targetDuration":10,"studyType":219,"phases":10,"briefSummary":220,"conditions":221,"keywords":10,"overallStatus":223,"whyStopped":10,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},{"fullName":5,"class":6},"Janssen Pharmaceutica N.V., Belgium","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Participants with Prostate Cancer (abiraterone acetate)",null,"Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.",{"label":13,"type":10,"description":14,"interventionNames":10},"Participants with Prostate Cancer (enzalutamide)","Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.",[16],{"name":17,"affiliation":5,"role":18},"Janssen Pharmaceutica N.V., Belgium Clinical Trial","STUDY_DIRECTOR",[20,30,37,44,53,60,67,74,81,88,95,102,109,116,123,130,137,141,148,155,162,169,176,183,190,197],{"facility":10,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Holstebro","Denmark","DK",{"type":25,"coordinates":26},"Point",[27,28],8.61607,56.36009,{"lat":28,"lon":27},{"facility":10,"status":10,"city":31,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":32,"geoPoint":36,"contacts":10},"Næstved",{"type":25,"coordinates":33},[34,35],11.76092,55.22992,{"lat":35,"lon":34},{"facility":10,"status":10,"city":38,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":39,"geoPoint":43,"contacts":10},"Odense",{"type":25,"coordinates":40},[41,42],10.38831,55.39594,{"lat":42,"lon":41},{"facility":10,"status":10,"city":45,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Besançon","France","FR",{"type":25,"coordinates":49},[50,51],6.01815,47.24878,{"lat":51,"lon":50},{"facility":10,"status":10,"city":54,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Beuvry",{"type":25,"coordinates":56},[57,58],2.68541,50.51674,{"lat":58,"lon":57},{"facility":10,"status":10,"city":61,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":10},"Bordeaux",{"type":25,"coordinates":63},[64,65],-0.58046,44.84124,{"lat":65,"lon":64},{"facility":10,"status":10,"city":68,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Challes-les-Eaux",{"type":25,"coordinates":70},[71,72],5.98098,45.54685,{"lat":72,"lon":71},{"facility":10,"status":10,"city":75,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Chalon-sur-Saône",{"type":25,"coordinates":77},[78,79],4.85372,46.78112,{"lat":79,"lon":78},{"facility":10,"status":10,"city":82,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":83,"geoPoint":87,"contacts":10},"Dijon",{"type":25,"coordinates":84},[85,86],5.01391,47.31344,{"lat":86,"lon":85},{"facility":10,"status":10,"city":89,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":90,"geoPoint":94,"contacts":10},"Lyon",{"type":25,"coordinates":91},[92,93],4.84789,45.74906,{"lat":93,"lon":92},{"facility":10,"status":10,"city":96,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":97,"geoPoint":101,"contacts":10},"Marseille",{"type":25,"coordinates":98},[99,100],5.38107,43.29695,{"lat":100,"lon":99},{"facility":10,"status":10,"city":103,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":104,"geoPoint":108,"contacts":10},"Paris",{"type":25,"coordinates":105},[106,107],2.3488,48.85341,{"lat":107,"lon":106},{"facility":10,"status":10,"city":110,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":111,"geoPoint":115,"contacts":10},"Quimper",{"type":25,"coordinates":112},[113,114],-4.09795,47.99597,{"lat":114,"lon":113},{"facility":10,"status":10,"city":117,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":118,"geoPoint":122,"contacts":10},"Saint-Mandé",{"type":25,"coordinates":119},[120,121],2.41579,48.83864,{"lat":121,"lon":120},{"facility":10,"status":10,"city":124,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":125,"geoPoint":129,"contacts":10},"Strasbourg",{"type":25,"coordinates":126},[127,128],7.74553,48.58392,{"lat":128,"lon":127},{"facility":10,"status":10,"city":131,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":132,"geoPoint":136,"contacts":10},"Toulouse",{"type":25,"coordinates":133},[134,135],1.44367,43.60426,{"lat":135,"lon":134},{"facility":10,"status":10,"city":138,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Berkshire","United Kingdom","UK",{"facility":10,"status":10,"city":142,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":143,"geoPoint":147,"contacts":10},"Birmingham",{"type":25,"coordinates":144},[145,146],-1.89983,52.48142,{"lat":146,"lon":145},{"facility":10,"status":10,"city":149,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":150,"geoPoint":154,"contacts":10},"Bolton",{"type":25,"coordinates":151},[152,153],-2.43333,53.58333,{"lat":153,"lon":152},{"facility":10,"status":10,"city":156,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":157,"geoPoint":161,"contacts":10},"Derby",{"type":25,"coordinates":158},[159,160],-1.47663,52.92277,{"lat":160,"lon":159},{"facility":10,"status":10,"city":163,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":164,"geoPoint":168,"contacts":10},"Glasgow",{"type":25,"coordinates":165},[166,167],-4.25763,55.86515,{"lat":167,"lon":166},{"facility":10,"status":10,"city":170,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":171,"geoPoint":175,"contacts":10},"Lancaster",{"type":25,"coordinates":172},[173,174],-2.79988,54.04649,{"lat":174,"lon":173},{"facility":10,"status":10,"city":177,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":178,"geoPoint":182,"contacts":10},"Middlesbrough",{"type":25,"coordinates":179},[180,181],-1.23483,54.57623,{"lat":181,"lon":180},{"facility":10,"status":10,"city":184,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":185,"geoPoint":189,"contacts":10},"Oldham",{"type":25,"coordinates":186},[187,188],-2.1183,53.54051,{"lat":188,"lon":187},{"facility":10,"status":10,"city":191,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":192,"geoPoint":196,"contacts":10},"Sutton",{"type":25,"coordinates":193},[194,195],-0.2,51.35,{"lat":195,"lon":194},{"facility":10,"status":10,"city":198,"state":10,"zip":10,"country":139,"countryCode":140,"cosmosGeoPoint":199,"geoPoint":203,"contacts":10},"Wolverhampton",{"type":25,"coordinates":200},[201,202],-2.12296,52.58547,{"lat":202,"lon":201},{"type":205,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100271464","a-study-to-investigate-the-impact-of-abiraterone-acetate-and-enzalutamide-on-health-related-quality-of-life-participant-reported-outcomes-and-medical-resource-use-in-metastatic-castration-resistant-prostate-cancer-participants-100271464",false,"NCT02813408","A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants","Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients","AQUARiUS","Inclusion Criteria:\n\n* Male 18 years of age or older\n* Participant with histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate\n* Participant with documented metastatic prostate cancer\n* Participant with documented castration resistance with progression of prostate cancer on androgen deprivation therapy (ADT)\n* Participant who will be initiated on either abiraterone acetate or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) that is asymptomatic or mildly symptomatic (per physician's evaluation) after failure of ADT at the time of treatment initiation\n* Participants who signed a participation agreement or Informed consent form (ICF) per local regulations\n* The treatment decision (abiraterone acetate or enzalutamide) by the treating physician must have been taken before enrollment into the study\n* Baseline patient-reported outcomes (PROs) must be captured before the first administration of abiraterone acetate or enzalutamide.\n\nExclusion Criteria:\n\n* Patient who has received any chemotherapy\u002Fcytotoxic agent to treat their mCRPC before abiraterone acetate or enzalutamide initiation; or ; treat their metastatic hormone-sensitive prostate cancer (mHSPC) \\\u003C12 months prior to abiraterone acetate or enzalutamide initiation.\n* Participant who is not capable of completing a patient survey\n* Participant who has received or is currently receiving abiraterone acetate or enzalutamide\n* Patient receiving an investigational treatment for prostate cancer of any kind before or at the time of initiation of abiraterone acetate or enzalutamide\n* Participant who is currently included in other observational studies with abiraterone acetate sponsored by Janssen","MALE","18 Years",{"count":217,"type":218},226,"ACTUAL","OBSERVATIONAL","The purpose of this observational study of metastatic castration-resistant prostate cancer (mCRPC) participants is to explore whether or not there are differences between participants treated with abiraterone acetate and enzalutamide on the health-related quality of life (HRQoL), Fatigue, Pain, Cognitive function and medical resource use (MRU).",[222],"Prostatic Neoplasms","COMPLETED","2019-05-23",{"date":226,"type":218},"2019-05-24",{"date":228,"type":218},"2016-05-03",{"date":230,"type":218},"2018-03-21",{"name":5,"class":6},26]